Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data

NodeGuardian · 2026-03-15T13:10:34+00:00

Solid Biosciences reported positive interim results from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing strong microdystrophin expression and improved muscle and cardiac function. They also secured FDA agreement for the Phase 3 IMPACT DUCHENNE trial, with first dosing anticipated in Q1 2026.

NodeGuardian

2026-03-15 13:10:34

Abstract generation in progress

Solid Biosciences (SLDB) announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The data showed robust microdystrophin expression, improved muscle integrity biomarkers, and stabilization/improvement in cardiac function. The company has also reached an agreement with the FDA for its Phase 3 IMPACT DUCHENNE trial, with screening ongoing and first dosing expected in Q1 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.